In this issue of Neuron, Espuny-Camacho et al. (2017) generate a humanized Alzheimer's disease (AD) model that reveals species-specific vulnerability of human neurons to AD pathology. This model provides key insights for disease mechanism and therapeutic discovery for AD.
Decades of intense research have markedly improved our understanding of the molecular and cellular bases of Alzheimer's disease (AD). Despite these advances, the current understanding on the disease mechanism of AD remains a work in progress (Canter et al., 2016; De Strooper and Karran, 2016) . One major challenge has been to establish the mechanistic link between the two prominent AD neuropathologic features, i.e., the accumulation of amyloid-b peptides in the forms of plaques (amyloid plaques) and neurofibrillary tangles consisting of prominent misfolded and hyperphosphorylated tau proteins (tau proteinopathies). The discoveries that patients with familial AD carry mutations in the amyloid precursor protein (APP) or presenilin (PSEN) genes have led to the amyloid hypothesis, which postulates that the progressive accumulation of abnormal amyloid peptides can trigger dysfunctions in a cascade of pathways leading to neurofibrillary tangle pathology and neuronal cell death. Although there is compelling evidence that amyloid pathology can indeed disrupt synaptic and neural circuit functions (Palop and Mucke, 2010) , whether a linear relationship exists between amyloid pathology and tau proteinopathies remains unclear.
Over the past few years, numerous attempts have been made to generate mouse models that recapitulate AD pathology and directly test the amyloid hypothesis. Indeed, a quick search in the Alzforum database reveals 123 animal models for AD, and similar search results can be found in the Jackson Laboratory website using keywords Alzheimer's disease and models. While some models are successful in capturing pathological features, including amyloid plaques, neuroinflammation, synaptic loss, and even neural circuit dysfunctions and cognitive impairment, no single model has been able to recapitulate tau proteinopathies in the form of neurofibrillary tangles in conjunction with amyloid pathology and neurodegeneration. One potential contributing factor to the disconnect between mouse models and human AD pathology could be a species-specific barrier to disease. To address this possibility, researchers have turned to using human induced pluripotent stem cells (iPSCs) or neural stem cells, which have mutations that model Down syndrome or familial AD, respectively, to study the pathology observed in AD (Choi et al., 2014; Shi et al., 2012) . While these in vitro threedimensional (3D) models recreated some of the classic AD phenotypes, including amyloid plaques and hyperphosphorylated tau proteins, it remains unclear whether these models can fully recapitulate the rich spatiotemporal and multicellular environment of the brain.
In a previous study, Espuny-Camacho and colleagues showed that human embryonic stem cells and iPSCs, when transplanted into mouse brain, can differentiate into cortical pyramidal neurons that extend axonal projections and dendritic arborization similar to the native mouse cortical neurons (Espuny-Camacho et al., 2013) . This study established that the mouse brain can provide a microenvironment conducive to the differentiation and integration of human neurons. Using a similar approach, the authors have now generated a humanized AD mouse model, in which human iPSC-derived cortical neurons were transplanted into transgenic Tg(Thy1-APPSw,Thy1-PSEN*L166P)21Jckr (APP/ PS1-21) mouse brain for 2 to 6 months (Espuny-Camacho et al., 2017) . Similar to the previous work, the transplanted human neurons exhibited cortical identity, expressed maturation markers, and integrated into the mouse host tissue forming multiple synapses. Comparisons between the human and mouse neurons showed that amyloid plaques within the human neuron clusters tended to have more diffuse morphology than the dense core plaques in mouse brain. The grafted human neurons were much more susceptible than the host mouse neurons to develop dystrophic neurites, characterized by heterogeneous clusters of vesicles, dense bodies, mitochondria, and neurofilament ( Figure 1 ). This effect was specific to the disease condition, as human neurons transplanted into wild-type mice didn't exhibit dystrophic neurites or signs of necrosis. In addition, the amyloid plaques in human neuron clusters showed reduced MAP2+ dendritic density and had a higher propensity for being surrounded by synaptophysin-positive (SYN+) and VGlut1-positive (VGlut1+) structures. The human neuron clusters also contained features of neuroinflammation with recruitment of host-derived phagocytic microglia and astrocytes that exhibited more hypertrophic features compared to those human neurons in wild-type mouse host tissue (Figure 1) .
In addition to the more severe AD pathology, human neurons in the APP/ PS1-12 mouse brain showed degenerative features, including reduced neuronal density and neuronal morphology consistent with necrosis. Furthermore, human neurons showed a progressive switch from 3R to 4R tau expression both at protein and RNA levels. At 4 months post transplantation (MPT), only 0.4% of human neurons expressed 4R tau, but by 6 MPT, 89% of human neurons expressed 4R tau. These results suggest that the 4R tau expression can be accelerated in this humanized AD model. To test this, Espuny-Camacho et al. (2017) transplanted iPSCs that carried tau Ex10+16 splicing mutation, which is associated with frontotemporal dementia (FTD) and favors 4R tau expression. Consistent with this idea, the expression of 4R tau was detected in 37% and 84% of human neurons at 4 and 6 MPT, respectively. In addition to the 3R/4R switch in tau expression, more hyperphosphorylated tau was detected in both human wild-type and tau Ex10+16 mutant neurons. Taken together, these results support the conclusion that human neurons are more susceptible to develop a full spectrum of AD pathology, including a greater degree of presynaptic vesicle accumulation, a reduction in the number of dendrites surrounding Ab plaques, a significant increase in neuronal necrotic cell death, and acceleration of tau proteinopathies. Finally, transcriptome analysis also revealed that transplanted human neurons adopted an AD-like gene expression signature (Zhang et al., 2013) .
Compared to the aforementioned 3D cell-based AD models, this humanized AD mouse model has several distinct advantages. First, it allows a long incubation period to capture a vaster number of key AD neuropathological features, including robust astrogliosis and microgliosis, synaptic and dendritic degeneration, neuronal cytoskeletal abnormalities, and the progressive 4R tau expression and tau hyperphosphorylation. Second, this model reveals previously unrecognized species-specific vulnerability of human cortical neurons to amyloid toxicity by direct comparison of human and mouse cortical neurons in the same host. Finally, the robust switch in 4R tau expression and tau hyperphosphorylation in wild-type human cortical neurons, and the overall transcriptomic signature in the grafted human tissues, lend further support that this humanized mouse model can be improved to provide more insights to the pathogenesis of AD, and ultimately, to directly test the amyloid hypothesis.
So, how can we improve it? One key approach is to drastically lengthen the incubation time of human iPSC-derived Although the host mouse neurons and the transplanted human neuron are exposed to Ab amyloid plaques and to host-derived microglia and astrocytes, the human neurons exhibit more prominent degenerative features, including reduced dendritic density (tan mesh-work), and more dystrophic neurites with accumulation of synaptophysin (SYP)+ and VGlut1+ structures near Ab amyloid plaques (yellow shaded areas). Furthermore, human neurons show evidence of necrosis, a switch to 4R tau expression, and accumulation of hyperphosphorylated tau (cyan helical structures in cytoplasm).
neurons to the maximal allowable time (1.5 to 2 years). The goal is to determine whether the full repertoire of tau proteinopathies, including the development of neurofibrillary tangles, can emerge as the iPSC-derived human neurons age in the AD mouse brain. Another approach is to transplant neurons that are directly reprogrammed from older control individuals to determine whether neurons that retain aging-associated genetic and epigenetic signatures are even more susceptible than iPSC-derived neurons to developing neurodegenerative features (Mertens et al., 2015; Vierbuchen et al., 2010) . A variation based on the same theme is to transplant neurons directly reprogrammed from fibroblasts from familial or late-onset AD patients into AD mouse brain to elucidate unknown mechanism(s) that contribute to the selective vulnerability of these patient-specific neurons.
Many genome-wide association studies have uncovered a growing list of genetic loci that increase the risk for AD. Results from these and others studies reinforce the idea that AD is a complex process fueled by a progressive dysregulation in interconnected mechanisms that eventually leads to cognitive decline (Canter et al., 2016; De Strooper and Karran, 2016) . Given the multitude of molecular pathways that can contribute to AD pathogenesis, one ultimate challenge is to determine whether this humanized AD mouse model can serve as a vehicle to identify therapeutic interventions that are tailored based on individual needs. To accomplish this, the humanized AD mouse model will need to be significantly improved to include a diverse cellular repertoire from the human grafts, including different neuronal subtypes, astrocytes, microglia, oligodendroglia, endothelial cells, and other vascular cell types. Our ability to incorporate these cell types will hopefully help develop a fully humanized model that provides insights to disease mechanisms and therapeutic targets.
In this issue of Neuron, Ben-Yaacov et al. (2017) dissect the interaction between AMPA receptors and auxiliary (TARP) subunits, revealing essential roles for the receptor transmembrane and cytoplasmic domains, as well as for the TARP extracellular EX2 loop.
Depolarizing current through AMPA receptors underlies fast excitatory transmission at glutamatergic synapses throughout the vertebrate central nervous system. Assisting AMPA receptors in this important task are an array of co-assembled auxiliary proteins (Jackson and Nicoll, 2011) , including members of the transmembrane AMPA receptor regulatory protein (TARP) family (Tomita, 2010) . The best-studied TARP, named stargazin or g2 TARP, was originally identified in a mutant mouse line. Stargazer mice exhibit ataxia with characteristic head elevation and frequent spike-wave discharges typical of absence seizures that produce brief loss of consciousness in humans. Recordings from cerebellar granule cells in these mice revealed a dramatic reduction in synaptic and AMPA-evoked currents, suggesting that g2 acts to chaperone AMPA receptor biosynthesis and/or promote forward trafficking to the surface membrane. Subsequent work led to identification of additional TARP family members as well as demonstration that co-assembly with TARPs induces a diverse array of changes in receptor kinetics and pharmacology (reviewed by Jackson and Nicoll, 2011; Tomita, 2010) . Recent structural (Twomey et al., 2016; Zhao et al., 2016) 
